Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer

被引:0
作者
Caressa Hui
Vera Qu
Jen-Yeu Wang
Rie von Eyben
Yu-Cheng Chang
Po-Lin Chiang
Chih-Hung Liang
Jen-Tang Lu
Gordon Li
Melanie Hayden-Gephart
Heather Wakelee
Joel Neal
Kavitha Ramchandran
Millie Das
Seema Nagpal
Scott Soltys
Nathaniel Myall
Erqi Pollom
机构
[1] Stanford University,Department of Radiation Oncology
[2] Vysioneer Inc,Department of Neurosurgery
[3] Stanford University,Department of Medical Oncology
[4] Stanford University,Department of Neurology
[5] Stanford University,Department of Radiation Oncology
[6] Stanford University,Department of Medical Oncology
[7] Stanford University,undefined
来源
Journal of Neuro-Oncology | 2022年 / 160卷
关键词
Radiation oncology; TKI; NSCLC; SRS; Osimertinib; Radiation;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:233 / 240
页数:7
相关论文
共 105 条
[1]  
Kim S-Y(2005)Screening of brain metastasis with limited Magnetic Resonance Imaging (MRI): clinical implications of using limited brain MRI during initial staging for non-small cell lung cancer patients J Korean Med Sci 20 121-126
[2]  
Kim J-S(2003)MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? Lung Cancer 42 189-193
[3]  
Park H-S(2015)Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: analysis from the European FRAME study Lung Cancer 90 427-432
[4]  
Hochstenbag MMH(2017)Epidermal growth factor receptor mutational status and brain metastases in non–small-cell lung cancer JGO 3 208-217
[5]  
Twijnstra A(2016)A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis? Oncotarget 7 56998-57010
[6]  
Hofman P(2017)Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer J Thorac Dis 9 2510-2520
[7]  
Moro-Sibilot D(2019)Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo plus ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC) Ann Oncol 30 v534-60
[8]  
Smit E(2019)Long-term survival of patients with melanoma with active brain metastases treated with Pembrolizumab on a phase II trial J Clin Oncol 37 52-465
[9]  
de Castro CJ(2012)Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial Lancet Oncol 13 459-730
[10]  
Bhatt VR(2018)Combined nivolumab and ipilimumab in melanoma metastatic to the brain N Engl J Med 379 722-873